Every article published in the Remy Peptides research library undergoes a structured editorial workflow before it reaches the public:
- Research & drafting — a team member with subject-matter expertise drafts the article, pulling data exclusively from primary and peer-reviewed sources.
- Internal review — a second reviewer cross-checks all numerical claims (weight-loss percentages, trial durations, sample sizes, p-values) against the cited source documents.
- Editorial sign-off — the Research Director reviews the article for scientific accuracy, regulatory-status accuracy, and internal consistency with the rest of the library before publication.
- Post-publication monitoring — published articles are flagged for review when new clinical data emerges, a regulatory decision changes, or a reader reports an issue.
We do not publish speculative claims. Where evidence is preliminary (conference abstracts, company press releases), we label it as such and distinguish it clearly from peer-reviewed findings.
The Remy Peptides research library is maintained by a team with professional backgrounds in:
- Pharmaceutical sciences — including pharmacology (PharmD), drug formulation, and peptide chemistry
- Biochemistry & analytical chemistry — HPLC method interpretation, mass spectrometry, and peptide stability analysis
- Clinical research methodology — Phase 2/3 trial design, biostatistics, and regulatory filing interpretation
All articles are published under the byline of Dr. Nadia Haroun, PharmD (Research Director), who reviews every article before publication. Contributors have direct experience reading and interpreting FDA regulatory filings, EMA assessments, and peer-reviewed publications in obesity and metabolic pharmacology.
Each article undergoes a four-point verification process:
- Data accuracy — every quantitative claim (efficacy percentages, adverse-event rates, dosing figures) is verified against the primary publication or regulatory document cited.
- Regulatory status — approval claims are confirmed against FDA databases, EMA registers, and ClinicalTrials.gov before publication and rechecked on a rolling basis.
- Date sensitivity — time-bound statements (e.g. “not yet approved as of March 2026”) are flagged in our editorial calendar for periodic reassessment.
- Cross-library consistency — data points referenced in multiple articles are compared to ensure no contradictions exist across the library.
Every factual claim in the research library is supported by at least one primary source. We prioritise sources in the following order:
- Peer-reviewed journals — The New England Journal of Medicine, The Lancet, JAMA, Nature Medicine, and specialty journals in endocrinology and obesity research. These are our gold standard for efficacy and safety data.
- Regulatory filings — FDA New Drug Applications, Prescribing Information labels, Breakthrough Therapy designations, Advisory Committee briefing documents, and EMA assessment reports.
- ClinicalTrials.gov — trial registrations, phase status, enrollment figures, primary completion dates, and protocol design documents.
- PubMed-indexed abstracts — used for supporting context, particularly for mechanism-of-action and pharmacokinetic data.
- Company press releases & conference abstracts — used only for pipeline timelines and preliminary results when no peer-reviewed data exists. Always labeled explicitly as company-reported or conference-reported.
We do not cite social media posts, online forums, anecdotal reports, other peptide vendor websites, or marketing materials as evidence. Pre-print servers are cited only when explicitly noted and when no peer-reviewed alternative is available.
We take accuracy seriously and correct confirmed errors promptly:
- Minor corrections (typos, broken links, formatting) are fixed immediately upon discovery.
- Factual corrections (incorrect data points, outdated regulatory status, misattributed findings) are corrected within 48 hours of confirmation. The article’s “Updated” date is changed, and the correction is logged in the article’s Update History section.
- Significant revisions (new trial data that materially changes the article’s conclusions) trigger a full editorial review. The article is updated with new data, the Update History section documents the change, and the article’s “Updated” date reflects the revision.
We do not silently alter published claims. All substantive changes are documented in the article’s visible Update History log.
Remy Peptides is a research peptide supplier that sells retatrutide. Our research library also covers compounds we do not sell, including tirzepatide, semaglutide, liraglutide, CagriSema, survodutide, orforglipron, petrelintide, zenagamtide, mazdutide, and VK2735.
We apply identical sourcing, verification, and editorial standards to all compounds regardless of whether we have a commercial interest. Specifically:
- Product references in articles are limited to a single clearly-separated footnote and do not influence editorial conclusions.
- Comparative articles present published clinical data without bias toward any compound.
- No pharmaceutical company, third-party brand, or advertiser has editorial influence over our content.
- The research team operates independently from commercial operations.
All content in the Remy Peptides research library is for informational and in-vitro laboratory research reference only. It is not intended to diagnose, treat, cure, or prevent any disease. Nothing published on this website constitutes medical advice.
Remy Peptides products are sold strictly for in-vitro laboratory research purposes. They are not approved for human or veterinary use. Consult a qualified healthcare professional for any medical decisions.
If you identify a factual error, outdated data point, broken citation, or any inaccuracy in our research library, we want to hear from you. Contact us with the article URL and the specific claim in question:
We review all correction requests and respond within 48 hours.
Last reviewed: March 2026